An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.
NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.
MI Cancer Seek has been granted FDA approval as a companion diagnostic for patients with cancer who may benefit from targeted therapy.
Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.
An abstract is unavailable.
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.
John Strickler, MD, Duke Cancer Institute, Durham, NC, gives an overview of the NICHE-2 trial (NCT03026140), which assessed immunotherapy for non-metastatic MSI-high colon cancer. Traditionally…
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
The Visitor Training Program (VTP) is intended to help build hematology capacity in developing countries by providing funding for hematologists or hematology-related health care professionals…
The Visitor Training Program (VTP) is intended to help build hematology capacity in developing countries by providing funding for hematologists or hematology-related health care professionals…
